Horizon Space Acquisition II Corp.

Horizon Space Acquisition II Corp.

SLBT
Horizon Space Acquisition II Corp.US flagNASDAQ Global Market
4.74
USD
-1.25
- -
37.53MMarket Cap
Horizon Space Acquisition II Corp.
SLBT
(NASDAQ Global Market)

Recent

price

4.74

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
FRC
- -
0.01
- -
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
- -
- -
Book Value per Share
0.01
0.01
- -
Tangible Book Value per Share
561
561
- -
Basic Weighted Avg Shares
1
3
2
Sales/Revenue/Turnover
11.02
-35.56
-174.65
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
-1
-4
Net Income, GAAP
25.12
- -
- -
Effective Tax Rate (%)
45.4
-35.42
-173.85
Profit Margin (%)
3
6
1
Working Capital
- -
- -
- -
LT Debt
4
6
2
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-60.12%
Free Cash Flow
- -
- -
-919.1%
Net Income, GAAP
- -
- -
220.63%
Sales/Revenue/Turnover
- -
- -
-34.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
SL Science Holding Limited, a Cayman Islands exempted holding company, operates as the post-business combination entity formed to own and control SL BIO Ltd., a biomedical company focused on cell and gene therapy platforms. The company engages in the development and commercialization of off-the-shelf gamma-delta T cell therapies and other cellular therapies targeting solid tumor indications, including pancreatic and brain cancers, with strategic capital and governance support from merged entities. Core activities include acquiring, owning, and coordinating SL BIO Ltd.’s clinical and commercial pipeline, providing overarching management, and pursuing partnerships, licensing, and financing to advance clinical development, regulatory filing, and eventual market commercialization. The group’s geographic footprint spans global operations through its subsidiaries and partnerships, with a headquarters presence in key financial centers enabling access to international capital markets. SL Science Holding Limited is publicly positioned to list on major exchanges, leveraging investor relations and strategic partnerships to support its growth trajectory in oncology therapeutics and biotech innovations. Founding year and headquarters are associated with its formation through a SPAC merger process, positioning the company to scale SL BIO Ltd.’s pipeline and accelerate clinical development, manufacturing scale-up, and potential commercial deployment. Subsidiaries and parent relationships include SL BIO Ltd. as the core operating entity, with governance and strategic oversight provided by the post-merger holding company.

Company News

APIChatGPT
  • SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • SL Science Holding Limited Reports Full Year 2025 Financial Results

  • SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market